Sense raises € 4.5 million to improve measurement of blood pressure


The Danish company Sense A/S just raised € 4.5 million for their groundbreaking medical technology for blood pressure measurement. The technology works seamlessly and will remedy incorrect diagnostics of hypertension at the physicians' offices, which themselves can cause elevated readings. The total investment from venture fund SEED Capital and Vækstfonden will be used to refine the product and for commercial launch in 2013.

High blood pressure affects more than ¼ of the Western world population and it is estimated that up to 12% of all deaths can be linked to this disorder. Hypertension is therefore one of the world's largest disease areas and the most important factor in the treatment of this is an accurate diagnosis. Current diagnostic solution of choice is the measurement of blood pressure at the physicians' offices, and typically using the cuff method. However this solution has a number of challenges including discomfort with the measurement itself and nervousness during the consultation which both may contribute to erroneous measurements. In addition, the realization is that a variety of cardiovascular diseases can be diagnosed much better by measuring blood pressure over a standard 24-hour circadian rhythm, and for this the cuff method is not very suitable.

The Danish company Sense A/S develops ContiPress™, which continuously measures the patient's blood pressure 24 hours a day, down to every 10 second day and night, without the user noticing. ContiPress™ consists of an intelligent patch, which the doctor or nurse places on the patient's upper arm. From there, the unit monitors the patient's blood pressure over 24 hours and stores the data for subsequent analysis via an enclosed piece of software. The result is comprehensive data about the patient's blood pressure over 24 hours and thus an optimal basis for making the correct diagnosis.

Sense has raised € 4.5 million in an investment round with venture fund SEED Capital and Vækstfonden. It is the company third round, since it was founded in 2006 in connection with an investment from SEED Capital. Second round of investment came from SEED Capital and Vækstfonden in 2010. ContiPress™ is currently a prototype that has been clinically tested on people with very large differences in both blood pressure, BMI (body mass index) and age with promising results that verify the measurement principle. The investment round will be used to refine the device and try ContiPress™ in a more extensive clinical testing within the expected commercial launch.

More info: 

News archive

  • 2014-04-16

    Oracain announces deal with Moberg Pharma

    The Danish biotech company Oracain, in whom SEED Capital is an investor, has reached a licensing agreement with the Swedish company Moberg Pharma. The deal entails licensing and development of Oracains main asset, a patented pill for pain relief, to Moberg Pharma.

  • 2014-04-11

    Gl. Hellerup High School builds new facilities using Abeos unique SL-Deck

    Since Abeo partnered with the concrete manufacturer Perstrup, earlier this year, they have been delivering their high-quality concrete solution, the SL-Deck, to the Danish construction industry.

  • 2014-04-08

    EpiTherapeutics raises more capital in order to retain their pole position

    EpiTherapeutics has raised another EUR 10.68 million in investments. The new investments have been raised among the EpiTherapeutics current investors, among them SEED Capital and Novo Seeds.

  • 2014-04-04

    Danish venture investments reach a record high!

    A recent analysis from Vækstfonden and DCVA concludes that SEED Capital and the other Danish venture capital firms have invested about DKK 2 billion in new start-up businesses in 2013.

  • 2014-04-04

    The startup team

    What to expect when approaching us with a start-up team and which measures do we take to secure every start-up the best possible foundation.

  • 2014-04-04

    Helle Uth joins the team at SEED Capital

    We are proud to announce that Helle Uth will be joining SEED Capital on the of April. Helle Uth will be the newest addition to the Technology Team and will be joining the team as Investment Manager.

  • 2014-04-04

    Napatech successfully lists on the Oslo Stock Exchange

    The Danish IT company Napatech has recently been listed on the Oslo Stock Exchange. This has further improved the company’s access to funding and thereby enables further growth. The IPO enables Napatech to manifest their position as the world’s leading supplier of network analysis adaptors.

  • 2014-04-04

    WatAgame hits it big with new social media application

    The SEED Capital funded Danish company watAgame has recently launched a popular social media application for kids. Momio, as the application is named, has become an instant success among kids and tweens in Denmark resulting in continuous top ten rankings in iOS App Store.

  • 2014-03-21

    Expanite have been ISO 9001 certified by German TÜV NORD

    The Danish start-up company Expanite obtained their ISO 9001 certification in February 2014. Since starting a treatment center in Hillerød the company has experienced a lot of interest in their technology.

  • 2014-03-12

    Alkalon appoints Bjarne Pedersen as CEO

    Alkalon has appointed Bjarne Pedersen as new CEO of the company. The founder and former CEO, Mr. Bo Tandrup, will continue in the company as Board Member and Executive Director focussing on research and new business development activities.




Where to meet us

2014-04-28 Line Holten Seminar: Om brugen af apps indenfor medicoindustrien Søhuset, SCION DTU, Hørshold
2014-05-07 Frank Knudsen EuroMedtech Linz, Austria
2014-05-21 Ulf Rosén MedTech Investing Conference Minneapolis, USA
2014-05-21 Jón Ingi Benediktsson BioEquity Europe Amsterdam, Netherlands
2014-05-27 Frank Knudsen High-Tech Gruenderfonds Family Day Bonn, Germany

Press Kit

SEED Capital Ulla Brockenhuus-Schack

SEED Capital logo
Download as png (8 kb)
Download as eps (374 kb)

Ulla Brockenhuus-Schack
Download as jpg (1.1 mb)

Download our full press kit here

Contact Information
Communication Manager Line Byrfelt Grønlykke
Phone: +45 4111 2191